Overview

* Senti Biosciences ( SNTI ) Q3 net loss was $18.1 mln, with EPS of -$0.69

* Cash and cash equivalents decreased to $12.2 mln from $48.3 mln at end of 2024

* R&D expenses rose to $10.5 mln, driven by higher external services and personnel costs

Result Drivers

* R&D EXPENSES - R&D expenses increased due to higher external services and personnel costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.69

Q3 Net -$18.1

Income mln

Q3 $16.95

Operatin mln

g

Expenses

Q3 -$16.95

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Senti Biosciences Inc ( SNTI ) is $12.00, about 84.2% above its November 12 closing price of $1.89

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)